Outcomes and Usability of Formoterol-Budesonide Delivered Through Synchrobreathe^® in Patients With Chronic Obstructive Pulmonary Disease: The EMERGE Study.

ABSTRACT:

Background

Chronic obstructive pulmonary disease (COPD) is a significant public health concern, and inhalation therapy is a critical component of its management. However, using an inhaler is challenging, especially for patients with COPD, who are often elderly and experience reduced dexterity, visual and cognitive impairment, and difficulty synchronizing inhalation with dose actuation. Synchrobreathe^® is an easy-to-use, breath-actuated inhaler that releases medication during inhalation, addressing these challenges. Although its use in asthma is well documented, evidence in COPD is limited.

Methods

This prospective, multicenter, observational study carried out during August 2021 and August 2022 evaluated the clinical outcomes of the budesonide/formoterol combinatio

SUBMITTER: Balamurugan S 

PROVIDER: S-EPMC12634959 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature